US2014206641A1PendingUtilityA1
Remedy
Est. expiryAug 27, 2022(expired)· nominal 20-yr term from priority
A61P 37/00A61P 37/04A61P 43/00A61P 37/06A61P 31/06A61P 33/02A61P 31/18A61P 29/00A61P 31/04A61P 35/00A61K 31/739A61P 1/04A61K 45/06A61K 31/496A61K 9/1647A61K 35/74A61K 31/00A61K 9/50A61K 47/34A61K 45/00A61K 9/1635Y02A50/30
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated.
Claims
exact text as granted — not AI-modified1 - 13 . (canceled)
14 . A method of treating AIDS comprising;
facilitating a phagocytic activity of macrophages by a lipopolysaccharide to activate the macrophages wherein the macrophages are infected by HIV; inducing a change of a membrane structure in the macrophages; inducing a membrane-bound tumor necrosis factor (TNF) in the macrophages, and inducing cell death of the macrophages.
15 . The method according to claim 14 , wherein the lipopolysaccharide is derived from Pantoea agglomerans.
16 . The method according to claim 14 , wherein the macrophages are MOLT-4 cells infected with HIV.Join the waitlist — get patent alerts
Track US2014206641A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.